|
1
|
Standl E, Khunti K, Hansen TB and Schnell
O: The global epidemics of diabetes in the 21st century: Current
situation and perspectives. Eur J Prev Cardiol. 26
(2_suppl):S7–S14. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sun H, Pouya P, Karuranga S, Pinkepank M,
Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et
al: IDF DiabetesAtlas:Global, regional and country-level diabetes
prevalence estimates for 2021 and projections for 2045. Diabetes
Res Clin Pract. 183(109119)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Romero-Martínez M, Barrientos-Gutiérrez T,
Cuevas-Nasu L, Bautista-Arredondo S, Colchero A, Gaona-Pineda EB,
Lazcano-Ponce E, Martínez-Barnetche J, Alpuche-Aranda C,
Rivera-Dommarco J and Shamah-Levy T: Metodología de la Encuesta
Nacional de Salud y Nutrición 2020 sobre Covid-19. Salud Publica
Mex. 63:444–451. 2021.PubMed/NCBI View
Article : Google Scholar : (In Spanish).
|
|
4
|
Intensive blood-glucose control with
sulphonylureas or insulin compared with conventional treatment and
risk of complications in patients with type 2 diabetes (UKPDS 33).
UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352:837–853.
1998.PubMed/NCBI
|
|
5
|
American Diabetes Association.
Introduction: Standards of Medical Care in Diabetes-2022. Diabetes
Care. 45 (Suppl 1):S1–S2. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
LaMoia TE and Shulman GI: Cellular and
molecular mechanisms of metformin action. Endocr Rev. 42:77–96.
2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Staiger H, Schaeffeler E, Schwab M and
Häring HU: Pharmacogenetics: Implications for modern type 2
diabetes therapy. Rev Diabet Stud. 12:363–376. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang C and Florez JC: Pharmacogenetics in
type 2 diabetes: Potential implications for clinical practice.
Genome Med. 3(76)2011.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Weizzman Institute of Science: Gene cards
SLC22A1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC22A1.
Accessed July 20, 2023.
|
|
10
|
Koepsell H, Lips K and Volk C:
Polyspecific organic cation transporters: Structure, function,
physiological roles, and biopharmaceutical implications. Pharm Res.
24:1227–1251. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lai Y: Organic anion, organic cation and
zwitterion transporters of the SLC22 and SLC47 superfamily (OATs,
OCTs, OCTNs and MATEs). In: Transporters in Drug Discovery and
Development. Woodhead Publishing, Sawston, 2013.
|
|
12
|
Goswami S, Gong L, Giacomini K, Altman RB
and Klein TE: PharmGKB summary: Very important pharmacogene
information for SLC22A1. Pharmacogenet Genomics. 24:324–328.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Becker ML, Visser LE, van Schaik RHN,
Hofman A, Uitterlinden AG and Stricker BH: Interaction between
polymorphisms in the OCT1 and MATE1 transporter and metformin
response. Pharmacogenet Genomics. 20:38–44. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
World Health Organization (WHO):
Definition and diagnosis of diabetes mellitus and intermediate
hyperglycemia: Report of a WHO/IDF consultation. WHO, Geneva, 2006.
https://iris.who.int/handle/10665/43588. Accessed
April 08, 2024).
|
|
15
|
Ortega-Ayala A, Rodríguez-Rivera NS,
Andrés F, Llerena A, Pérez-Silva E, Espinosa-Sánchez AG and
Molina-Guarneros JA: Pharmacogenetics of metformin transporters
suggests no association with therapeutic inefficacy among diabetes
type 2 mexican patients. Pharmaceuticals (Basel).
15(774)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Health Secretary: Official Mexican
Normative NOM-177-SSA1-2013 [Internet]. DOF2013. http://www.dof.gob.mx/nota_detalle.php?codigo=5314833&fecha=20/09/2013.
Accessed September 17, 2023.
|
|
17
|
US Department of Health and Human
Services, Food and Drug Administration (FDA), Center for Drug
Evaluation and Research (CDER) and Center for Veterinary Medicine
(CVM): Bioanalytical Methods Validation, Guidance for lndustry.
https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
Accessed May 24, 2018.
|
|
18
|
Shamah Levy T, Cuevas Nasu L, Morales Ruan
MC, Mundo Rosas V, Méndez Gómez-Humarán I and Villalpando Hernández
S: Profile of the health and nutritional status of older adults in
Mexico. 2012 National Health and Nutrition Survey. J Frailty Aging.
2:184–191. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
World Health Organization (WHO): Physical
Status: The Use of and Interpretation of Anthropometry, Report of a
WHO Expert Committee. WHO, Geneva, 1995. https://apps.who.int/iris/handle/10665/37003.
Accessed July 21, 2023.
|
|
20
|
Reséndiz-Abarca CA, Flores-Alfaro E,
Suárez-Sánchez F, Cruz M, Valladares-Salgado A, Del Carmen
Alarcón-Romero L, Wacher-Rodarte NA and Gómez-Zamudio JH: Altered
glycemic control associated with polymorphisms in the SLC22A1
(OCT1) Gene in a Mexican population with type 2 diabetes mellitus
treated with metformin: A cohort study. J Clin Pharmacol.
59:1384–1390. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Menjivar M, Sánchez-Pozos K,
Jaimes-Santoyo J, Monroy-Escutia J, Rivera-Santiago C, de Los
Ángeles Granados-Silvestre M and Ortiz-López MG: Pharmacogenetic
evaluation of metformin and sulphonylurea response in mexican
mestizos with type 2 diabetes. Curr Drug Metab. 21:291–300.
2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Christensen MH, Brasch-Andersenb C, Greene
H, Nielsen F, Damkierc P, Beck-Nielsen H and Brosena K: The
pharmacogenetics of metformin and its impact on plasma metformin
steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet
Genomics. 21:837–850. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhou K, Donnelly LA, Kimber CH, Donnan PT,
Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN
and Pearson ER: Reduced-function SLC22A1 polymorphisms encoding
organic cation transporter 1 and glycemic response to metformin: A
GoDARTS study. Diabetes. 58:1434–1439. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Umamaheswaran G, Praveen RG, Damodaran SE,
Das AK and Adithan C: Influence of SLC22A1 rs622342 genetic
polymorphism on metformin response in South Indian type 2 diabetes
mellitus patients. Clin Exp Med. 15:511–517. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dujic T, Causevic A, Bego T, Malenica M,
Velija-Asimi Z, Pearson ER and Semiz S: Organic cation transporter
1 variants and gastrointestinal side effects of metformin in
patients with type 2 diabetes. Diabet Med. 33:511–514.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shu Y, Sheardown SA, Brown C, Owen RP,
Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et
al: Effect of genetic variation in the organic cation transporter 1
(OCT1) on metformin action. J Clin Invest. 117:1422–1431.
2007.PubMed/NCBI View
Article : Google Scholar
|
